IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal

IGBA Statement on trade barriers and their impact on… 25 March 2025
Impact of extending the duration of regulatory data… 14 February 2024 In the context of the new EU pharmaceutical legislation, this…
Position on the Proposal for a Regulation of the European… 19 June 2023 Medicines for Europe welcomes the introduction of harmonised labelling, notably…
IQVIA - Assessing the Biosimilar Void 30 October 2023 While biosimilar competition in Europe has played a vital role…